Semaglutide and tirzepatide are among 20 new additions to the WHO's list of essential medicines.
In new Phase III trial data released Tuesday, people taking orforglipron lost substantially more weight than people taking a placebo.
The Danish pharmaceutical company has struggled in recent months to meet its lofty sales expectations.
The federal government is expected to start a 5-year-long experiment that will provide some limited coverage of obesity medications.
In early animal tests, the experimental TDN triggered weight loss without nausea or vomiting.
People who took semaglutide over a slower, more flexible schedule were significantly less likely to experience nausea and to discontinue use.
New research published Tuesday concludes that the rising rate of extreme childhood obesity—well above the usual BMI cutoff—has become a "public health emergency."
New research finds that men taking a GLP-1 for their obesity or type 2 diabetes often experience a rise in testosterone levels.
People taking Amgen's MariTide lost up to 20% of their body weight in a Phase II trial.
Patients on GLP-1 medications lost about half as much weight as participants did in clinical trials, NYU researchers found.
By pairing semaglutide with one or two experimental antibodies designed to preserve muscle, participants lost less lean body mass while still trimming pounds.
New research finds that ER visits related to semaglutide use might be on the rise.
New research shows that nearly everyone with a obese BMI would be considered obese using other common tests.
A recent survey reveals the foods that people are less likely to eat once they start taking GLP-1 medications like Ozempic.
Stanford Medicine researchers have identified a promising, naturally occurring molecule that could help people lose weight—without the nauseating symptoms now commonly seen with GLP-1 drugs.
New research suggests humans and labradors might be predisposed to gaining weight for similar reasons.
Alexandra Sowa's new book The Ozempic Revolution is intended to be the "first comprehensive user guide" to GLP-1 drugs like Ozempic.
People who stayed on a 7.2 milligram weekly dose of semaglutide lost around 20% of their body weight over 72 weeks.
An international and widely supported group of experts is pushing doctors to avoid the exclusive use of BMI to decide whether someone has obesity, alongside other major changes.
A new review highlights the future of anti-obesity medications that could outperform today's already blockbuster drugs like Ozempic.
